As of 2025-05-29, the Intrinsic Value of Kiadis Pharma NV (KDS.AS) is -0.01 EUR. This KDS.AS valuation is based on the model Peter Lynch Fair Value. With the current market price of 5.46 EUR, the upside of Kiadis Pharma NV is -100.25%.
Based on its market price of 5.46 EUR and our intrinsic valuation, Kiadis Pharma NV (KDS.AS) is overvalued by 100.25%.
Note: result may not be accurate due to the invalid valuation result of Peter Lynch's fair value model.
Range | Selected | Upside | |
a | |||
Fair Value | -0.01 - -0.01 | -0.01 | -100.25% |
P/E | (17.16) - (18.09) | (18.70) | -442.4% |
DDM - Stable | (40.15) - 1,025.54 | 492.69 | 8923.7% |
DDM - Multi | (22.41) - 473.61 | (48.65) | -991.0% |
Market Cap (mil) | 220.09 |
Beta | 5.24 |
Outstanding shares (mil) | 40.31 |
Enterprise Value (mil) | 220.74 |
Market risk premium | 6.62% |
Cost of Equity | 6.76% |
Cost of Debt | 5.00% |
WACC | 6.66% |